


Setting the standard in renal denervation

The Symplicity Spyral™ system is a complementary hypertension treatment option backed by evidence unmatched in scope, quantity and quality.



Unmatched Evidence

>25,000


Patients treated globally with the Symplicity™ RDN system¹

>4,000

Patients enrolled in the global clinical program²⁻⁶

Significant

Consistent blood pressure reductions in 4 sham-controlled trials²⁻⁵




Safe

Excellent safety profile^{2-7,10}

No new incidence of renal artery stenosis at 6 months⁵

Minimal decline in eGFR through 3 years¹⁰




Sustained

Only renal denervation with Symplicity Spyral™ System has demonstrated lasting blood pressure reductions at 3 years.⁶⁻⁸

18 mmHg reduction in OSBP at 3 years. n=267¹¹


Real-world results

Significant BP reductions across high-risk subgroups at 3 years in GSR



Always on

RDN demonstrates 24-hr BP-lowering effect especially during high-risk night-time and early morning periods³



- [†] Resistant hypertension defined as OSBP>150 mmHg, ≥3 anti-hypertensive medications.
- [‡] CKD defined as eGFR <60ml/min/1.73m²
- ¹ Medtronic Data on File. RDN Catheter Historic Data, June 2023. Data includes both Symplicity Flex and Symplicity Spyral.
- ² Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. *The Lancet*. 2017; 390(10108):2160-2170.
- ³ Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. *The Lancet*. 2020;395(10234): 1444-51.
- ⁴ Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. *The Lancet*. 2018 Jun 9;391(10137):2346-2355.

- ⁵ Kandzari DE. Renal denervation in the presence of anti-hypertensive medications: six-month results from the randomized, blinded, sham-controlled SPYRAL HTN-ON MED trial. Presented at AHA Nov. 2022.
- ⁶ Mahfoud F, Mancia G, Schmieder R, et al. Renal Denervation in high-risk patients with hypertension. *J Am Coll Cardiol*. 2020; 75:2879-2888.
- ⁷ Schlaich M, Mahfoud F, Williams B, et al. Long-Term Safety and Efficacy of Renal Denervation with the Symplicity Spyral Catheter in the Global SYMPLECTIC Registry. *Am Soc Neph Kidney Week* 2021.
- ⁸ Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. *The Lancet*. 2022; 399:1401-1410.
- ⁹ Mahfoud F, et al. Blood pressure reduction after catheter-based renal denervation in patients with cardiovascular disease in the Global SYMPLECTIC Registry. *ESH* 2022.
- ¹⁰ Symplicity Spyral™ Renal Denervation System. Sponsor Executive Summary. US FDA Circulatory Systems Devices Panel. Meeting date August 23, 2023.
- ¹¹ Medtronic data on file, GSR DEFINE analysis, Apr 2023.

medtronic.eu/RDN

UC202402055-spyral-clinical-summary-one-pager-en-emea-10505603 © 2023 Medtronic. Medtronic logo and Engineering the extraordinary are trademarks of Medtronic. Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company. Not for distribution in the USA, Japan, or France.

See the device manual for information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at www.medtronic.eu.

Medtronic

Explore the evidence